Cargando…

Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies

BACKGROUND: There is scarcity of data on outcome of COVID-19 in patients with hematological malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality. Secondary objectives were to correlate age, comorbidities and remission status with outcome. METHODS: Retrospective mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Borah, Pronamee, Mirgh, Sumeet, Sharma, Sanjeev Kumar, Bansal, Sachin, Dixit, Ashish, Dolai, Tuphan Kanti, Lunkad, Sweta, Gupta, Naveen, Singh, Gurmeet, Jain, Aditi, Bansal, Divya, Choudhary, Dharma, Khandelwal, Vipin, Doval, Divya, Kumar, Meet, Bhargava, Rahul, Chakrabarti, Amrita, Kalashetty, Mallikarjun, Rauthan, Amit, Kazi, Bilal, Mandal, Prakas Kumar, Jeyaraman, Preethi, Naithani, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723067/
https://www.ncbi.nlm.nih.gov/pubmed/33338697
http://dx.doi.org/10.1016/j.bcmd.2020.102525
Descripción
Sumario:BACKGROUND: There is scarcity of data on outcome of COVID-19 in patients with hematological malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality. Secondary objectives were to correlate age, comorbidities and remission status with outcome. METHODS: Retrospective multicentre observational study conducted in 11 centres across India. Total 130 patients with hematological malignancies and COVID-19 were enrolled. RESULTS: Fever and cough were commonest presentation. Eleven percent patients were incidentally detected. Median age of our cohort was 49.5 years. Most of our patients had a lymphoid malignancy (n = 91). One-half patients (52%) had mild infection, while moderate and severe infections contributed to one-fourth each. Sixty seven patients (52%) needed oxygen For treatment of COVID-19 infection, half(n = 66) received antivirals. Median time to RT-PCR COVID-19 negativity was 17 days (7–49 days). Nearly three-fourth (n = 95) of our patients were on anticancer treatment at time of infection, of which nearly two-third (n = 59;64%) had a delay in chemotherapy. Overall, 20% (n = 26) patients succumbed. 14-day survival and 28-day survival for whole cohort was 85.4% and 80%, respectively. One patient succumbed outside the study period on day 39. Importantly, death rate at 1 month was 50% and 60% in relapse/refractory and severe disease cohorts, respectively. Elderly patients(age ≥ 60) (p = 0.009), and severe COVID-19 infection (p = 0.000) had a poor 14-day survival. The 28-day survival was significantly better for patients in remission (p = 0.04), non-severe infection (p = 0.00), and age < 60 years (p = 0.05). CONCLUSIONS: Elderly patients with hematological malignancy and severe covid-19 have worst outcomes specially when disease is not in remission.